C
HLB테라퓨틱스
115450KOSDAQ54.5 / 100
Reference Date: 2026-10-23
Financial Score20.0 / 40
News Sentiment12.5 / 25
Momentum12.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Surged 30.9% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
HLB Therapeutics operates three core business divisions: biopharma, cold chain, and electronics. Through numerous mergers and acquisitions since 2013, the company has diversified its business, and after divesting its electronics division in 2024, it continues to transition toward a biopharma-focused structure. Its main revenue streams come from vaccine pharmaceuticals and distribution fees.
Number of Employees
50people
Average Salary
48.6M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.004.0Point
PBR
1.44Industry Average 1.202.5Point
Higher than industry avg (caution)
ROE
-5.44Industry Average 8.000.0Point
Well below industry avg
Debt Ratio
16.44Industry Average 100.008.0Point
Half of industry avg (excellent)
Trend 2023~20255.5 / 10 points
Revenue Growth Rate
2.5 / 3
Avg ▲14.4% (2-year basis)
Operating Profit Growth Rate
3.0 / 3
Avg ▲33.0% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -6.9% (declining, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position5.0Point
52w mid range (47%)
Current 2,650Won52-week high 3,98052-week low 1,451
1-month return6.0Point
1m +30.86% (strong rise)
Volume trend1.0Point
Volume decreasing
Detailed Disclosure
3 totalPositive 0Neutral 3Negative 0
- Neutral주식등의대량보유상황보고서(일반)2026-10-21
- Neutral기업설명회(IR)개최2026-10-12
- Neutral주식등의대량보유상황보고서(일반)2026-10-02